|
Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
|
03 August 2016 |
|
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
|
28 June 2016 |
|
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
|
15 June 2016 |
|
Novartis highlights its strong foundation for long-term, sustainable growth
|
25 May 2016 |
|
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
|
18 May 2016 |
|
Novartis Foundation and partners launch innovative hypertension program in Vietnam
|
17 May 2016 |
|
Novartis delivered solid Q1 despite Gleevec loss of exclusivity
|
21 April 2016 |
|
Novartis shareholders approve all resolutions proposed by Board of Directors
|
23 February 2016 |
|
Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
|
18 February 2016 |
|
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
|
11 February 2016 |